This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

Novo Nordisk (NVO) announced on Friday that it has secured a legal victory against compounders selling unauthorized versions ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

‘The face has a layer of fat that essentially stretches the skin. Ozempic results in rapid weight loss and does so very ...

Now, alarmed by sunken features and sagging skin, newly svelte patients are flooding med spas and plastic surgery clinics, desperate to plump, lift and smooth their way back to a youthful glow. These ...

US President Donald Trump’s recent weight loss has become the talk of the town after his recent medical exam revealed a ...

You cannot legally walk into a shop and buy weight loss injections without a prescription. But licensed retailers and clinics ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

Eli Lilly ( LLY 3.84%) and Novo Nordisk ( NVO 2.01%) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global sales ...